China's CanSino to offer tens of millions of COVID-19 vaccines to COVAX
BEIJING - China's CanSino Biologics Inc has proposed providing "tens of million of doses" of its single-dose COVID-19 vaccine to global vaccine sharing scheme COVAX, Reuters quoted a senior executive of the company as saying.
Pierre Morgon, senior vice president at CanSino, told the media outlet in an interview that the firm made the proposal in December last year to supply vaccines between late 2021 and the end of 2022.
"We are happy to go beyond 2022 if there was still an expectation to do so," Morgon was quoted in the report on Thursday.
The offering to COVAX, which is backed by the World Health Organization, is the lowest price that CanSino uses in markets outside China, where richer countries are subject to prices about three times higher, the report added.
- Sino-foreign youth dialogue promotes mutual understanding in Nanning
- Surfing in Guangdong's Shantou
- Macao SAR to speed up reform, diversification in 2026: chief executive
- China's primary school population peaks, middle school to follow
- China's express delivery sector posts steady growth in first 10 months
- Intl visitors embrace nature, biodiversity at Tianmu Mountain
